IP Library › Granted Patent US 12,357,201
Granted Patent B2
US 12,357,201 · App. 16/504,175 · Granted Jul 15, 2025

System and method for mode switching

Inventors: Naresh C. Bhavaraju (San Diego, CA); Michael A. Bloom (Carlsbad, CA); Leif N. Bowman (San Diego, CA); Alexandra Lynn Carlton (San Marcos, CA); Katherine Yerre Koehler (Solana Beach, CA); Hari Hampapuram (Carlsbad, CA); Jonathan Hughes (Encinitas, CA); Lauren Hruby Jepson (San Diego, CA); Apurv Ullas Kamath (San Diego, CA); Anna Leigh Rack-Gomer (Cardiff by the Sea, CA); Peter C. Simpson (Cardiff, CA); Stephen J. Vanslyke (Carlsbad, CA)
Assignee: Dexcom, Inc.
A61B5/14532A61B5/0002A61B5/14503A61B5/14546A61B5/1455A61B5/1486A61B5/1495A61B5/7221A61B5/7275A61B5/7282A61B5/742A61B5/7435A61B5/746A61B5/7475A61M5/1723G16H40/40G16H40/63A61B5/0004A61B5/6898A61B5/72A61B2560/0223A61B2560/0487A61M2230/005A61M2230/201Y02A90/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,201
App. No.
16/504,175
Granted
Jul 15, 2025
Kind
B2
Abstract

Systems and methods described provide dynamic and intelligent ways to change the required level of user interaction during use of a monitoring device. The systems and methods generally relate to real time switching between a first or initial mode of user interaction and a second or new mode of user interaction. In some cases, the switching will be automatic and transparent to the user, and in other cases user notification may occur. The mode switching generally affects the user's interaction with the device, and not just internal processing. The mode switching may relate to calibration modes, data transmission modes, control modes, or the like.

Claims (63)

1. A method implemented by a processor of a monitoring device including sensor electronics coupled to only one glucose sensor, the method comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a glucose level indicated by the measurement data fails to satisfy a clinical usability threshold in response to the glucose level satisfying a 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor; and

in response to the glucose level satisfying the 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy the 40 mg/dL low threshold glucose value for the only one glucose sensor, automatically transitioning the monitoring device to a second decision support mode and modifying the user interface to display a second visual indication that the monitoring device is operating in the second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

2. A system for monitoring glucose, the system comprising:

only one glucose sensor and sensor electronics coupled to the only one glucose sensor; and

a monitoring device in signal communication with the sensor electronics, the monitoring device including a processor and non-transitory computer readable media storing instructions that are executable by the processor to perform operations comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a glucose level indicated by the measurement data fails to satisfy a clinical usability threshold in response to the glucose level satisfying a 400 mg/dl high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor; and

in response to the glucose level satisfying the 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy the 40 mg/dL low threshold glucose value for the only one glucose sensor, automatically transitioning the monitoring device to a second decision support mode and modifying the user interface to display a second visual indication that the monitoring device is operating in the second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

3. A method implemented by a processor of a monitoring device including sensor electronics coupled to only one glucose sensor, the method comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a real time glucose value indicated by the measurement data fails to satisfy a clinical usability threshold in response to the real time glucose value satisfying a high threshold glucose value for the only one glucose sensor or in response to the real time glucose value failing to satisfy a low threshold glucose value for the only one glucose sensor; and

in response to the real time glucose value satisfying the high threshold glucose value for the only one glucose sensor or in response to the real time glucose value failing to satisfy the low threshold glucose value for the only one glucose sensor, automatically transitioning the monitoring device to a second decision support mode and modifying the user interface to display a second visual indication that the monitoring device is operating in the second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

4. A system for monitoring glucose, comprising:

only one glucose sensor and sensor electronics coupled to the only one glucose sensor; and

a monitoring device in signal communication with the sensor electronics, the monitoring device including a processor and non-transitory computer readable media storing instructions that are executable by the processor to perform operations comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a real time glucose value indicated by the measurement data fails to satisfy a clinical usability threshold in response to the real time glucose value satisfying a high threshold glucose value for the only one glucose sensor or in response to the real time glucose value failing to satisfy a low threshold glucose value for the only one glucose sensor; and

in response to the real time glucose value satisfying the high threshold glucose value for the only one glucose sensor or in response to the real time glucose value failing to satisfy the low threshold glucose value for the only one glucose sensor, automatically transitioning the monitoring device to a second decision support mode and modifying the user interface to display a second visual indication that the monitoring device is operating in the second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

5. The method of claim 1 , wherein controlling insulin dosage by the insulin pump while the monitoring device is in the first decision support mode comprises at least one of:

disabling the insulin pump during a low glucose phase responsive to detecting low glucose levels in the measurement data;

outputting an alarm indicating low glucose levels responsive to detecting low glucose levels and disabling the insulin pump after outputting the alarm; or

updating the user interface to display a visual indication of an insulin dosage calculated by the monitoring.

6. The method of claim 1 , further comprising displaying an indication of a current performance metric for the only one glucose sensor on the user interface.

7. The method of claim 1 , wherein the second visual indication indicates the expected duration that the monitoring device will be operating in the second decision support mode.

8. The method of claim 1 , wherein evaluating the clinical usability of the measurement data is further performed using external data obtained from one or more sources other than the only one glucose sensor.

9. A method implemented by a processor of a monitoring device including sensor electronics coupled to only one glucose sensor, the method comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a glucose level indicated by the measurement data fails to satisfy a clinical usability threshold in response to the glucose level satisfying a 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor; and

in response to the glucose level satisfying the 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor, automatically transitioning the monitoring device to a second decision support mode and modifying the user interface to display a second visual indication that the monitoring device is operating in the second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

10. The method of claim 9 , wherein controlling insulin dosage by the insulin pump while the monitoring device is in the first decision support mode comprises at least one of:

disabling the insulin pump during a low glucose phase responsive to detecting low glucose levels in the measurement data;

outputting an alarm indicating low glucose levels responsive to detecting low glucose levels and disabling the insulin pump after outputting the alarm; or

updating the user interface to display a visual indication of an insulin dosage calculated by the monitoring device.

11. The method of claim 9 , further comprising displaying an indication of a current performance metric for the only one glucose sensor on the user interface.

12. The method of claim 9 , wherein the second visual indication indicates the expected duration that the monitoring device will be operating in the second decision support mode.

13. The method of claim 9 , wherein evaluating the clinical usability of the measurement data is further performed using external data obtained from one or more sources other than the only one glucose sensor.

14. A system for monitoring glucose, the system comprising:

only one glucose sensor and sensor electronics coupled to the only one glucose sensor; and

a monitoring device in signal communication with the sensor electronics, the monitoring device including a processor and non-transitory computer readable media storing instructions that are executable by the processor to perform operations comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a glucose level indicated by the measurement data fails to satisfy a clinical usability threshold in response to the glucose level satisfying a 400 mg/dl high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor; and

in response to the glucose level satisfying the 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor, automatically transitioning the monitoring device to a second decision support mode and modifying the user interface to display a second visual indication that the monitoring device is operating in the second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

15. The system of claim 14 , wherein controlling insulin dosage by the insulin pump while the monitoring device is in the first decision support mode comprises at least one of:

disabling the insulin pump during a low glucose phase responsive to detecting low glucose levels in the measurement data;

outputting an alarm indicating low glucose levels responsive to detecting low glucose levels and disabling the insulin pump after outputting the alarm; or

updating the user interface to display a visual indication of an insulin dosage calculated by the monitoring device.

16. The system of claim 14 , wherein the second visual indication indicates the expected duration that the monitoring device will be operating in the second decision support mode.

17. A method implemented by a processor of a monitoring device including sensor electronics coupled to only one glucose sensor, the method comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a glucose level indicated by the measurement data fails to satisfy a clinical usability threshold in response to the glucose level satisfying a 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor; and

in response to the glucose level satisfying the 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor:

automatically transitioning the monitoring device to a second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump; and

modifying the user interface to display a second visual indication that indicates the monitoring device is operating in the second decision support mode and indicates an expected duration that the monitoring device will be operating in the second decision support mode, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

18. A system for monitoring glucose, the system comprising:

only one glucose sensor and sensor electronics coupled to the only one glucose sensor; and

a monitoring device in signal communication with the sensor electronics, the monitoring device including a processor and non-transitory computer readable media storing instructions that are executable by the processor to perform operations comprising:

receiving measurement data from the sensor electronics indicative of a glucose concentration measured by the only one glucose sensor and causing display of the glucose concentration on a user interface together with a first visual indication that the monitoring device is operating in a first decision support mode, the first decision support mode including the monitoring device controlling insulin dosage by an insulin pump coupled to the monitoring device;

evaluating a clinical usability of the measurement data and determining that a glucose level indicated by the measurement data fails to satisfy a clinical usability threshold in response to the glucose level satisfying a 400 mg/dL high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor; and

in response to the glucose level satisfying the 400 mg/dl high threshold glucose value for the only one glucose sensor or in response to the glucose level failing to satisfy a 40 mg/dL low threshold glucose value for the only one glucose sensor:

automatically transitioning the monitoring device to a second decision support mode, the second decision support mode preventing the monitoring device from calculating an insulin dosage amount or controlling insulin dosage by the insulin pump; and

modifying the user interface to display a second visual indication that indicates the monitoring device is operating in the second decision support mode and indicates an expected duration that the monitoring device will be operating in the second decision support mode, wherein the first visual indication further indicates that the glucose concentration is useable for clinically reliable insulin dosing and the second visual indication further indicates that the glucose concentration is not useable for clinically reliable insulin dosing, and further indicating an expected duration that the monitoring device will be operating in when operating in the second decision support mode.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2020
From: BHAVARAJU, NARESH C.; BLOOM, MICHAEL A.; BOWMAN, LEIF N.; CARLTON, ALEXANDRA LYNN; HAMPAPURAM, HARI; HUGHES, JONATHAN; JEPSON, LAUREN HRUBY; KAMATH, APURV ULLAS; RACK-GOMER, ANNA LEIGH; SIMPSON, PETER C.; VANSLYKE, STEPHEN J.
To: DEXCOM, INC.
Reel/Frame 052335/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2020
From: GRUBSTEIN, KATHERINE YERRE
To: DEXCOM, INC.
Reel/Frame 052335/0894 →
Continuity (4)
Continuation 15060401 · Mar 3, 2016
Continuation 14862079 · Sep 22, 2015
Provisional Application 62053733 · Sep 22, 2014
Related Publication 20190328291A1 · Oct 31, 2019
References Cited (90)
US 5267152A · Yang · 1993 [cited by examiner]
US 7591801B2 · Brauker et al. · 2009 [cited by applicant]
US 7783442B2 · Mueller et al. · 2010 [cited by applicant]
US 7885697B2 · Brister et al. · 2011 [cited by applicant]
US 7946985B2 · Mastrototaro et al. · 2011 [cited by applicant]
US 7976492B2 · Brauker et al. · 2011 [cited by applicant]
US 8423381B2 · Gegner et al. · 2013 [cited by applicant]
US 8442610B2 · Goode et al. · 2013 [cited by applicant]
US 8460231B2 · Brauker et al. · 2013 [cited by applicant]
US 8579879B2 · Palerm et al. · 2013 [cited by applicant]
US 8721585B2 · Brauker et al. · 2014 [cited by applicant]
US 8808228B2 · Brister et al. · 2014 [cited by applicant]
US 8882741B2 · Brauker et al. · 2014 [cited by applicant]
US 8920401B2 · Brauker et al. · 2014 [cited by applicant]
US 8926585B2 · Brauker et al. · 2015 [cited by applicant]
US 9050413B2 · Brauker et al. · 2015 [cited by applicant]
US 9155843B2 · Brauker et al. · 2015 [cited by applicant]
US 9452258B2 · Dobbles et al. · 2016 [cited by applicant]
US 9452259B2 · Dobbles et al. · 2016 [cited by applicant]
US 9457146B2 · Dobbles et al. · 2016 [cited by applicant]
US 9463277B2 · Dobbles et al. · 2016 [cited by applicant]
US 11903697B2 · Bhavaraju et al. · 2024 [cited by applicant]
US 20030100846A1 · Custer et al. · 2003 [cited by applicant]
US 20050027180A1 · Goode et al. · 2005 [cited by applicant]
US 20050043598A1 · Goode, Jr. et al. · 2005 [cited by applicant]
US 20060020192A1 · Brister · 2006 [cited by examiner]
US 20070208246A1 · Brauker et al. · 2007 [cited by applicant]
US 20070258395A1 · Jollota et al. · 2007 [cited by applicant]
US 20080161664A1 · Mastrototaro · 2008 [cited by examiner]
US 20080228045A1 · Gao et al. · 2008 [cited by applicant]
US 20080234663A1 · Yodfat et al. · 2008 [cited by applicant]
US 20090005666A1 · Shin et al. · 2009 [cited by applicant]
US 20090006034A1 · Hayter et al. · 2009 [cited by applicant]
US 20090112478A1 · Mueller et al. · 2009 [cited by applicant]
US 20090178459A1 · Li et al. · 2009 [cited by applicant]
US 20090192366A1 · Mensinger et al. · 2009 [cited by applicant]
US 20100057041A1 · Hayter · 2010 [cited by applicant]
US 20100138197A1 · Sher · 2010 [cited by applicant]
US 20100174168A1 · Goode, Jr. et al. · 2010 [cited by applicant]
US 20100249561A1 · Patek et al. · 2010 [cited by applicant]
US 20100262434A1 · Shaya · 2010 [cited by examiner]
US 20100332142A1 · Shadforth et al. · 2010 [cited by applicant]
US 20110015944A1 · Gegner et al. · 2011 [cited by applicant]
US 20110178820A1 · Soni et al. · 2011 [cited by applicant]
US 20110191044A1 · Stafford · 2011 [cited by applicant]
US 20110213559A1 · Pollack et al. · 2011 [cited by applicant]
US 20120029942A1 · Katsuki et al. · 2012 [cited by applicant]
US 20120078071A1 · Bohm et al. · 2012 [cited by applicant]
US 20120083714A1 · Yuen et al. · 2012 [cited by applicant]
US 20120108935A1 · Liang et al. · 2012 [cited by applicant]
US 20120125075A1 · Gottlieb · 2012 [cited by examiner]
US 20120220979A1 · Brauker et al. · 2012 [cited by applicant]
US 20120265037A1 · Bohm · 2012 [cited by examiner]
US 20120271557A1 · Sekimoto et al. · 2012 [cited by applicant]
US 20130218126A1 · Hayter et al. · 2013 [cited by applicant]
US 20140000338A1 · Luo et al. · 2014 [cited by applicant]
US 20140005505A1 · Peyser et al. · 2014 [cited by applicant]
US 20140012510A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140039383A1 · Dobbles et al. · 2014 [cited by applicant]
US 20140277286A1 · Cinbis · 2014 [cited by applicant]
US 20140288494A1 · Brister et al. · 2014 [cited by applicant]
US 20150164387A1 · Varsavsky et al. · 2015 [cited by applicant]
US 20150165117A1 · Palerm · 2015 [cited by examiner]
US 20160081597A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20160106350A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20160113557A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20160113558A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20160198988A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20190328292A1 · Bhavaraju et al. · 2019 [cited by applicant]
US 20200275870A1 · Bhavaraju et al. · 2020 [cited by applicant]
US 20250025071A1 · Bhavaraju et al. · 2025 [cited by applicant]
EP 1718350B1 · 2013 [cited by applicant]
GB 2488487A · 2012 [cited by applicant]
WO 2004109992A1 · 2004 [cited by applicant]
WO WO2008086541 · 2008 [cited by applicant]
WO WO2008086541A3 · 2008 [cited by applicant]
WO 2008086541A9 · 2008 [cited by applicant]
WO 2012178134A2 · 2012 [cited by applicant]
WO WO2015156965 · 2015 [cited by applicant]
WO 2015187366A1 · 2015 [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2015/051548 mailed on Apr. 6, 2017, 7 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2015/051548 mailed on Dec. 16, 2015, 9 pages. [cited by applicant]
U.S. Provisional Application No. 201462053733P, inventors Bowman; Leif N. et al., filed on Sep. 22, 2014. [cited by applicant]
Notice of Opposition from European application No. 15778109.7, mailed Sep. 21, 2021, 48 pages. [cited by applicant]
Office Action from Australian Patent Application No. 2019202148, dated Jan. 20, 2021, 5 pages. [cited by applicant]
Office Action from Australian Patent Application No. 2019202148, dated Mar. 16, 2021, 3 pages. [cited by applicant]
Office Action from Canadian Patent Application No. 2,953,577, dated May 3, 2021, 5 pages. [cited by applicant]
Bothe M.K., et al., “The use of Reinforcement Learning Algorithms to meet the challenges of an Artificial Pancreas”, Expert Review Medical Devices, vol. 10(5), 2013, pp. 661-673. [cited by applicant]
Dexcom Inc., “Dexcom G4 Platinum Continuous Glucose Monitoring System Quick Start Guide,” 2013, 2 pages. [cited by applicant]
Vaddiraju S., et al., “Technologies for Continuous Glucose Monitoring: Current Problems and Future Promises”, Journal of Diabetes Science and Technology, vol. 4(6), Nov. 2010, pp. 1540-1562. [cited by applicant]